Mono Pharmacre Ltd Stock Price Today (NSE: MONOPHARMA)
Fundamental Score
Mono Pharmacre Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Mono Pharmacre Ltd share price today is ₹12.00, down 2.04% on NSE/BSE as of 22 June 2026. Mono Pharmacre Ltd (MONOPHARMA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹37.02 (Cr). The 52-week high for MONOPHARMA share price is ₹27.50 and the 52-week low is ₹9.45. At a P/E ratio of 44.60x, MONOPHARMA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 10.42% and a debt-to-equity ratio of 1.76.
Mono Pharmacre Ltd Share Price Chart — NSE/BSE Historical Performance
Mono Pharmacre Ltd share price chart: -6.49% return over the past month. 52-week high ₹27.50, 52-week low ₹9.45.
Mono Pharmacre Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | 2.00K (Cr) | |
| ₹11.45 | ₹12.25 | ₹11.45 | ₹12.25 | 6.00K (Cr) | |
| ₹12.45 | ₹12.45 | ₹11.35 | ₹11.40 | 12.00K (Cr) | |
| ₹12.50 | ₹12.50 | ₹12.50 | ₹12.50 | 2.00K (Cr) | |
| ₹13.00 | ₹13.10 | ₹13.00 | ₹13.10 | 4.00K (Cr) | |
| ₹12.50 | ₹12.50 | ₹12.50 | ₹12.50 | 2.00K (Cr) | |
| ₹13.25 | ₹13.25 | ₹13.25 | ₹13.25 | 2.00K (Cr) | |
| ₹12.30 | ₹13.10 | ₹12.30 | ₹13.10 | 6.00K (Cr) | |
| ₹11.15 | ₹11.50 | ₹11.15 | ₹11.50 | 4.00K (Cr) | |
| ₹11.15 | ₹11.50 | ₹11.15 | ₹11.15 | 66.00K (Cr) |
Mono Pharmacre Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | +0.00% | |
| ₹12.50 | ₹13.10 | ₹11.35 | ₹12.25 | -2.00% | |
| ₹11.15 | ₹13.25 | ₹11.15 | ₹13.25 | +18.83% | |
| ₹12.20 | ₹12.20 | ₹11.15 | ₹11.15 | -8.61% | |
| ₹9.50 | ₹12.00 | ₹9.45 | ₹12.00 | +26.32% | |
| ₹14.50 | ₹14.50 | ₹9.45 | ₹9.90 | -31.72% | |
| ₹19.90 | ₹19.90 | ₹14.50 | ₹15.20 | -23.62% | |
| ₹20.50 | ₹21.60 | ₹19.70 | ₹20.55 | +0.24% | |
| ₹22.05 | ₹24.00 | ₹19.00 | ₹20.00 | -9.30% | |
| ₹22.50 | ₹25.50 | ₹20.65 | ₹22.05 | -2.00% | |
| ₹24.25 | ₹27.50 | ₹22.50 | ₹22.50 | -7.22% | |
| ₹25.65 | ₹26.45 | ₹22.80 | ₹23.90 | -6.82% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Mono Pharmacre Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Mono Pharmacre Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MONOPHARMA across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Balanced Promoter Holding (56.72%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Premium Valuation Risk (P/E: 44.60x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-99.13%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-23.94%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Elevated Debt Levels (D/E: 1.76)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (1.35x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Mono Pharmacre Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Mono Pharmacre Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Mono Pharmacre LtdMono Pharmacre ...Selected✓ MONOPHARMA • | 11.8/100 | ₹12.00₹12 | ₹37.02₹37.02 | 44.60Average 44.6 Average | 10.42%Average 10.42% Average | 11.00%Average 11.00% Average | 1.76Average 1.8 Average | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Mono Pharmacre Ltd PE Ratio History
Historical price-to-earnings ratio for MONOPHARMA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹1.58 | ₹34.65 | 21.9x |
| FY 2023 | ₹0.70 | ₹49.00 | 70.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Mono Pharmacre Ltd Quarterly Performance
Latest quarterly metrics for MONOPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-23.94%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-99.13%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Mono Pharmacre Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for MONOPHARMA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Mono Pharmacre Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Mono Pharmacre Ltd (MONOPHARMA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Mono Pharmacre Ltd
About MONOPHARMA (Mono Pharmacre Ltd)
Mono Pharmacre Ltd (MONOPHARMA) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a c...urrent market capitalisation of ₹37.02 (Cr). Mono Pharmacre Ltd has delivered a Return on Equity (ROE) of 10.42% and a ROCE of 11.00%. The debt-to-equity ratio stands at 1.76, reflecting the company's capital structure. Investors tracking MONOPHARMA share price can monitor key metrics including P/E ratio, promoter holding of 56.72%, and quarterly earnings growth.
Company Details
MONOPHARMA Share Price: Frequently Asked Questions
What is the current share price of Mono Pharmacre Ltd?
Mono Pharmacre Ltd (MONOPHARMA) trades at ₹12.00 on NSE. Market cap ₹37.02 (Cr). Educational data only.
What is the P/E ratio of Mono Pharmacre Ltd?
Mono Pharmacre Ltd has a P/E of 44.60x vs industry average 31.77x.
What is the Bull Run score for Mono Pharmacre Ltd?
Mono Pharmacre Ltd has a Bull Run score of 11.8/100 based on 25+ financial parameters.
Does Mono Pharmacre Ltd pay dividends?
Mono Pharmacre Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Mono Pharmacre Ltd?
Mono Pharmacre Ltd has ROE of 10.42%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Mono Pharmacre Ltd?
Mono Pharmacre Ltd has debt-to-equity of 1.76.
Is Mono Pharmacre Ltd a good investment?
Bull Run gives Mono Pharmacre Ltd a score of 11.8/100. This is not investment advice — consult a SEBI-registered advisor.